Home Categories Esomeprazole magnesium trihydrate
A4037912

Esomeprazole magnesium trihydrate , Pharmaceutical level , 217087-09-7

Synonym(s):
(S)-Omeprazole magnesium trihydrate

CAS NO.:217087-09-7

Empirical Formula: C34H38MgN6O7S2

Molecular Weight: 731.14

MDL number: MFCD07698573

EINECS: 669-839-3

Pack Size Price Stock Quantity
1G RMB23.20 In Stock
5g RMB67.20 In Stock
10G RMB111.20 In Stock
25g RMB218.40 In Stock
100g RMB788.00 In Stock
others     Enquire
Update time: 2022-07-08

PRODUCT Properties

Melting point: 184-189°C (dec.)
storage temp.  Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
solubility  Slightly soluble in water, soluble in methanol, practically insoluble in heptane.
form  Solid
color  White to off-white
InChI InChI=1S/2C17H18N3O3S.Mg.H2O/c2*1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;;/h2*5-8H,9H2,1-4H3;;1H2/q2*-1;+2;
InChIKey VEVZQDGATGBLIC-UHFFFAOYSA-N
SMILES C(C1N=CC(C)=C(OC)C=1C)S1C2[N-]C3=CC(OC)=CC=C3N=2[Mg+2]2(O=S(CC3N=CC(C)=C(OC)C=3C)C3[N-]C4=CC(OC)=CC=C4N2=3)O=1.O
CAS DataBase Reference 217087-09-7(CAS DataBase Reference)

Description and Uses

esomeprazole magnesium trihydrate for the healing of peptic ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy.

  1. Zollinger-Ellison syndrome
  2. Peptic ulcer, site unspecified
  3. Duodenal ulcer
  4. Gastric ulcer
  5. Gastro-oesophageal reflux disease
Esomeprazole belongs to the family of medications known as proton pump inhibitors (PPIs). Esomeprazole is registered by the Therapeutic Goods Administration (TGA) for the following indications:
  1. Gastro-Oesophageal Reflux Disease (GORD):
  2. treatment of erosive reflux oesophagitis;
  3. long-term management of patients with healed oesophagitis to prevent relapse;
  4. symptomatic treatment of gastro-oesophageal reflux disease (GORD).
In combination with appropriate antibiotics for:
  1. healing of duodenal ulcer associated with Helicobacter pylori;
  2. eradication of Helicobacter pylori in patients with active or healed peptic ulcer.
  3. Short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug (NSAID) (non-selective and COX-2 selective) therapy.
  4. Healing of gastric ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy.
  5. Prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy in patients at risk.

Safety

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H302
Precautionary statements  P301+P312+P330
Hazard Codes  Xn
Risk Statements  22
WGK Germany  3
HS Code  2933399090

RELATED PRODUCTS